pediatric B-progenitor acute lymphoblastic leukemia , Hispanic / Latino ethnicity , and a poor outcome in IKZF 1 alteration of kinases , JAK is associated with mutation of CRLF 2 Rearrangement of

Downing and Cheryl L. Willman Devidas, W. Paul Bowman, Bruce M. Camitta, Gregory H. Reaman, Stephen P. Hunger, James R. Carroll, Huining Kang, Wei Liu, Kevin K. Dobbin, Malcolm A. Smith, William L. Carroll, Meenakshi Richard C. Harvey, Charles G. Mullighan, I-Ming Chen, Walker Wharton, Fady M. Mikhail, Andrew J. pediatric B-progenitor acute lymphoblastic leukemia , Hispanic/Latino ethnicity, and a poor outcome in IKZF1 alteration of kinases, JAK is associated with mutation of CRLF2 Rearrangement of

[1]  S. Gupta,et al.  Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 2014, Kathmandu University medical journal.

[2]  J. Downing,et al.  Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.

[3]  Takashi Akasaka,et al.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.

[4]  M. Loh,et al.  JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[5]  Christopher B. Miller,et al.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.

[6]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[7]  G. Wainreb,et al.  Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome , 2008, The Lancet.

[8]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[9]  D. Teachey,et al.  Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. , 2007, Cancer research.

[10]  M. Rocchi,et al.  Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphoma , 2007, Leukemia.

[11]  D. Ghosh,et al.  COPA - cancer outlier profile analysis , 2006, Bioinform..

[12]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[13]  J. Downing,et al.  Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Armstrong,et al.  Molecular genetics of acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Cumano,et al.  Pre-B cell receptor expression is necessary for thymic stromal lymphopoietin responsiveness in the bone marrow but not in the liver environment. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[17]  H. Drexler,et al.  Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation , 2001, Leukemia.

[18]  F. Behm,et al.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.

[19]  D. Largaespada,et al.  Cloning of the Murine Thymic Stromal Lymphopoietin (Tslp) Receptor , 2000, The Journal of experimental medicine.

[20]  Heinz Baumann,et al.  Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin , 2000, Nature Immunology.

[21]  N. Copeland,et al.  Molecular cloning of a novel type 1 cytokine receptor similar to the common gamma chain. , 2000, Blood.

[22]  A. Look,et al.  Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse , 1999 .

[23]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[24]  R. Perlmutter,et al.  Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism. , 1999, Journal of immunology.

[25]  N. Heerema,et al.  Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies , 1998, Cancer.

[26]  C. Paige,et al.  Characterization of thymic stromal‐derived lymphopoietin (TSLP) in murine B cell development in vitro , 1996, European journal of immunology.

[27]  S. Shurtleff,et al.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. , 1995, Leukemia.

[28]  J. Downing,et al.  11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Williams,et al.  A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. , 1994, Experimental hematology.

[30]  S. Schwartz.  Myeloproliferative Disorders , 1975, Annals of surgery.

[31]  J. Downing,et al.  Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. , 2010, Blood.

[32]  R. Arceci,et al.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study , 2009 .

[33]  A. Pardanani.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.

[34]  R. Tibshirani,et al.  Outlier sums for differential gene expression analysis. , 2007, Biostatistics.

[35]  M. Hirai,et al.  Molecular cloning of a human novel type I cytokine receptor related to delta1/TSLPR. , 2001, Cytogenetics and cell genetics.

[36]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .